Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The major players in the hep C pharmaceutical market are still reaching for improved treatments, with two key approvals expected this year.
“We need drugs that are gentler, kinder, better and cheaper.”
ViiV Healthcare recently acquired Bristol-Myers Squibb’s (BMS) portfolio of HIV antiretrovirals (ARVs) in the pipeline.
The HIV drug development pipeline is robust, with 12 novel agents and fixed-dose combinations (FDCs) in Phase II or III studies—and seve...
The first of a two-part look at the top treatment news of 2010.
In the past month, two companies shelved their once-promising experimental HIV drugs, citing the challenging nature of bringing a...
GlaxoSmithKline and Pfizer announced November 3 the launch of ViiV Healthcare, a collaboration between both pharmaceutical companies.
A new non-nuke, the apparent cure of an HIV-positive patient receiving a bone marrow transplant and the possibility of earlier...
Recently, Three HIV drugs got stuck in clinical trials. Why? Here’s a look at the twists and turns of drug approval.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.